summary
Monheit Law has launched a new website for individuals who took blood thinner Xarelto and suffered an adverse event in the form of a serious personal injury. The goal of the site is to provide up to date news on the pending Xarelto lawsuits. For more info call: 877-646-0035 Continue reading
prREACH
Jan 25, 2016 /prREACH/ -- Monheit Law has announced the launch of their new resource website which is designed to provide the public with exclusive Xarelto Lawsuit news. To create the site, they have partnered with several other dedicated U.S. Law Firms. It is designed to be a valuable resource for people across the country, and a tool which will help injured victims pursue justice.
The website is designed to provide users with the most current information on Xarelto multidistrict litigation number 2592, which is being overseen in Louisiana by the Honorable Judge Eldon Fallon. MDL 2592 is currently composed of over 2,800 cases federally-filed against manufacturers Bayer AG and Janssen Pharmaceuticals, (a subdivision of the well-known Johnson & Johnson corporation).
Plaintiffs involved in the lawsuits commonly allege that blood-thinning drug Xarelto can cause dangerous uncontrollable bleeding episodes for those using it, and that manufacturers were both reckless and negligent to release the drug to market without any corresponding antidote for emergency situations.
Without an antidote, if a patient taking Xarelto suffers even minor injuries and begins to bleed, physicians will be unable to clot their blood. In these circumstances, the physicians are required to resort to extreme life-saving measures such as surgeries to drain pooling blood and relieve pressure; or blood transfusions to prevent the loss of too much blood. Patients in these situations are at significant risk of passing away, or suffering from lifelong complications.
Unlike Xarelto, traditional blood thinners do not have this issue. They offer an antidote in vitamin K. When a patient using a traditional blood thinner becomes injured, doctors can treat them with vitamin K to clot their blood--a difference which could potentially save their life.
The website also discusses Pradaxa, as Pradaxa is a similar new-generation of blood thinner which has already settled its mounting lawsuits. Pradaxa was manufactured by Boehringer Ingelheim in 2010. Quickly after the product’s release to market, it was surrounded by more than 3,500 reports of serious health complications. More than 750 of these reports were fatal. Just one day before the trial against Boehringer Ingelheim was to begin, the company agreed to pay $650 million to plaintiffs to settle their lawsuits. This comparison can provide valuable information for Xarelto plaintiffs today as they look ahead to future trials.
In addition to providing this information, the website also details the findings of various critical studies which have been highlighted in Xarelto lawsuits, linking the drug to a number of serious injuries with potentially lasting or even deadly effects.
Those who have used Xarelto and have suffered from adverse effects which they attribute to the drug may be entitled to significant compensation. Anyone interested in exploring their legal rights in the matter is encouraged to visit bloodthinnerhelp.com and reach out to the attorneys at Monheit Law to request additional information or ask questions. Monheit Law is currently offering free consultations to affected individuals.